PTSM: Pharmaceutical Technology Sourcing and Management, Jan 31, 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Jan 31, 2007
Global Feature
Changing Fortunes in Pharmaceutical Manufacturing
By Patricia Van Arnum
Pfizer's restructuring plan provides yet another example of new supply-chain strategies by the pharmaceutical majors, which involve rationalization of manufacturing facilities and cost improvement. A review of these moves, an outlook for the pharmaceutical market in 2007, and analysis of US pharmaceutical production and trade.
Pharma Partner Focus
3M Drug Delivery Systems Advances Inhalation and Transdermal Drug Delivery
By Patricia Van Arnum
Following the sales of its global branded pharmaceutical business, 3M stays the course in drug delivery as its Drug Delivery Systems Division advances technology in inhalation and transdermal drug delivery.
Outsourcing
Simpler is Better
By Jim Miller
The recent struggles of Cardinal Health's and Patheon's contract dose manufacturing businesses offer a lesson on good business practices.
News
Agreements and contracts
The latest pacts from the pharmaceutical supply chain.
People
People on the move in January 2007.
Mergers, acquisitions, and restructuring
A roundup of company moves and positioning from the pharmaceutical and biotechnology industries and contract service providers.
Expansions
A roundup of manufacturing and service expansions for January 2007.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here